Dupilumab for systemic allergy syndrome with dermatitis
Abstract
Allergic contact dermatitis (ACD) has been traditionally identified as TH1-mediated delayed-type hypersensitivity reactions. There is currently no Food and Drug Administration-approved systemic therapy indicated for ACD. Among patients with ACD, there is a subgroup that experience not only concomitant atopic dermatitis and ACD but also systemic allergic dermatitis driven by allergens encountered through dietary consumption. Basic science and clinical studies have supported the notion that ACD involves a complex interaction between both TH1 and TH2 axes of the secondary immune system on an allergen-by-allergen basis. Herein, we report the patients with systemic allergy syndrome with dermatitis to either Balsam of Peru or nickel who achieved remarkable improvement and regained their quality of life without continuing adherence to strict diets. Our study suggests that dupilumab may be an efficacious solution for a particular subgroup of patients with recalcitrant ACD when first- and second-line therapies have failed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There have been multiple reports demonstrating the effectiveness of dupilumab in the treatment of ACD.
“There have been multiple reports demonstrating the effectiveness of dupilumab in the treatment of ACD (eTable).[12][13][14][15][16][17][18][19][20]”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [18]
Findings from these studies show that dupilumab can improve recalcitrant dermatitis caused by a broad range of contact allergens, including nickel.
“The findings from these studies show that dupilumab can improve recalcitrant dermatitis caused by a broad range of contact allergens, including nickel.”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [18]
Several studies have reported successful use of dupilumab for systemic ACD.
“Notably, several studies have reported successful use of dupilumab for systemic ACD.12,18”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [18]
Cited by
Sorted by citations
Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing.
Johnson, H. (2022) · Current Psychiatry · doi:10.12788/cutis.0519 · Cited by 20 · see citing works
- Authors
- Jacob, S. E., Sung, C. T., & Machler, B. C.
- Affiliations
- Loma Linda University (US)
- University of California, Riverside (US)
- New York University (US)
- Corresponding author
- Jacob, Sharon E.
- ORCID
- Jacob, Sharon E.
- Venue
- Dermatitis®
- Publisher
- SAGE Publications
- Published
- 2019-04-01
- Volume
- 30
- Issue
- 2
- Pages
- 164-167
- ISSN
- 1710-3568 (ISSN-L)
- 2162-5220
- OpenAlex
- W2919335361
- Cited by
- 28
- References
- 0
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 5
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Dermatitis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- dupilumab, allergic contact dermatitis, atopic dermatitis, balsam of Peru, nickel allergy, food allergens, Th1/Th2 balance, quality of life
- MeSH terms
- Adult, Aged, Antibodies, Monoclonal, Dermatitis, Atopic, Female, Humans, Male, Middle Aged, Interleukin-4, Dermatitis, Allergic Contact, Anti-Allergic Agents, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
